Claims for Patent: 10,960,052
✉ Email this page to a colleague
Summary for Patent: 10,960,052
Title: | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Abstract: | The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine. |
Inventor(s): | Sauerberg; Per (Farum, DK), Bjerregaard; Simon (Hilleroed, DK), Nielsen; Flemming Seier (Federikssund, DK) |
Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
Application Number: | 16/118,381 |
Patent Claims: |
1. A solid composition for oral administration comprising a GLP-1 agonist, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, magnesium stearate, povidone, and
microcrystalline cellulose, wherein the GLP-1 agonist is semaglutide, wherein the composition comprises at least 60% (w/w) of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.
2. The composition according to claim 1, wherein the composition comprises 0.1-10% (w/w) of the magnesium stearate, 0.1-10% (w/w) of the povidone, and 5-40% (w/w) of the microcrystalline cellulose; and wherein the sum of the magnesium stearate, the povidone, and the microcrystalline cellulose is no more than 40% (w/w) of the composition. 3. The composition according to claim 2, wherein the composition comprises 0.5-5% (w/w) of the magnesium stearate. 4. The composition according to claim 3, wherein the composition comprises 1-3.5% (w/w) of the magnesium stearate. 5. The composition according to claim 4, wherein the composition comprises 1% (w/w) of the magnesium stearate. 6. The composition according to claim 2, wherein the composition comprises 0.2-4% (w/w) of the povidone. 7. The composition according to claim 6, wherein the composition comprises 0.5-3% (w/w) of the povidone. 8. The composition according to claim 7, wherein the composition comprises 1% (w/w) or 2% (w/w) of the povidone. 9. The composition according to claim 2, wherein the composition comprises 10-30% (w/w) of the microcrystalline cellulose. 10. The composition according to claim 9, wherein the composition comprises 5-25% (w/w) of the microcrystalline cellulose. 11. The composition according to claim 10, wherein the composition comprises a percentage (w/w) of the microcrystalline cellulose selected from the group consisting of 10.9% (w/w), 18% (w/w), 19.5% (w/w), and 20.5% (w/w). 12. A solid composition for oral administration comprising a semaglutide, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, a lubricant, a binder, and a filler, wherein the composition comprises at least 60% (w/w) of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the composition comprises 1-3.5% (w/w) of the magnesium stearate, wherein the composition comprises 0.5-3% (w/w) of the povidone, and wherein the composition comprises 5-25% (w/w) of the microcrystalline cellulose. 13. The composition according to claim 12, wherein the composition comprises 2% (w/w) of the povidone. 14. The composition according to claim 12, wherein the composition comprises at least 70% (w/w) of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 15. The composition according to claim 14, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). 16. The composition according to claim 15, wherein the composition comprises 2% (w/w) of the povidone. 17. A solid composition for oral administration comprising semaglutide, N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC), a lubricant, a binder, and a filler, wherein the composition comprises 300 mg of SNAC, wherein the composition comprises 1-3.5% (w/w) of the magnesium stearate, wherein the composition comprises 0.5-3% (w/w) of the povidone, and wherein the composition comprises 5-25% (w/w) of the microcrystalline cellulose. 18. The composition according to claim 17, wherein the composition comprises 2% (w/w) of the povidone. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.